炎症性肠病患者生物制剂治疗药物监测的适宜应用
该指南采用改良德尔菲法,由国际炎症性肠病专家对28条关于生物制剂治疗药物监测(TDM)的陈述进行投票,24条(86%)达成共识。共识认为抗肿瘤坏死因子(anti-TNF)治疗可在诱导后及维持期至少一次进行主动TDM,而其他生物制剂不适用;所有生物制剂在原发无应答和继发失应答时均适用被动TDM。
要点
- 抗TNF治疗诱导后及维持期至少一次主动TDM被认为适宜,其他生物制剂不适用。
- 所有生物制剂在原发无应答和继发失应答时被动TDM均适宜。
- 特定临床场景下药物及抗药抗体浓度阈值达成多项共识。
核心结论
- 共识认为TDM在炎症性肠病生物制剂治疗中有应用价值,尤其是抗TNF治疗;非抗TNF生物制剂需更多数据以进一步定义最佳药物浓度和抗药抗体阈值。
研究设计与样本
- 采用改良德尔菲法建立共识,先进行全面文献回顾并提交国际炎症性肠病专家,随后由专家对28条关于TDM临床应用的陈述按1至10分评分(1=强烈不同意,10=强烈同意)。
主要发现
- 专家小组就24条(86%)陈述达成共识。
- 抗TNF治疗诱导后及维持期至少一次主动TDM被认为适宜,其他生物制剂不适用。
- 所有生物制剂在原发无应答和继发失应答时被动TDM均适宜。
- 专家小组还就特定临床场景下生物制剂的TDM及适宜的药物和抗药抗体浓度阈值达成多项共识。
关键数值与推荐
- 陈述接受标准为80%或以上参与者同意且评分≥7分。
- 抗TNF治疗主动TDM适宜于诱导后及维持期至少一次。
- 所有生物制剂在原发无应答和继发失应答时被动TDM均适宜。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需要更多数据,尤其是关于非抗TNF生物制剂,以进一步定义最佳药物浓度和抗药抗体阈值,因为这些阈值可能因评估的治疗结局而异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Therapeutic drug monitoring (TDM) is widely available for biologic therapies in patients with inflammatory bowel disease (IBD). We reviewed current data and provided expert opinion regarding the clinical utility of TDM for biologic therapies in IBD. METHODS: We used a modified Delphi method to establish consensus. A comprehensive literature review was performed regarding the use of TDM of biologic therapy in IBD and presented to international IBD specialists. Subsequently, 28 statements on the application of TDM in clinical practice were rated on a scale of 1 to 10 (1 = strongly disagree and 10 = strongly agree) by each of the panellists. Statements were accepted if 80% or more of the participants agreed with a score ≥7. The remaining statements were discussed and revised based on the available evidence followed by a second round of voting. RESULTS: The panel agreed on 24 (86%) statements. For anti-tumor necrosis factor (anti-TNF) therapies, proactive TDM was found to be appropriate after induction and at least once during maintenance therapy, but this was not the case for the other biologics. Reactive TDM was appropriate for all agents both for primary non-response and secondary loss of response. The panellists also agreed on several statements regarding TDM and appropriate drug and anti-drug antibody (ADA) concentration thresholds for biologics in specific clinical scenarios. CONCLUSION: Consensus was achieved towards the utility of TDM of biologics in IBD, particularly anti-TNF therapies. More data are needed especially on non-anti-TNF biologics to further define optimal drug concentration and ADA thresholds as these can vary depending on the therapeutic outcomes assessed.
引用
- Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2019. PMID: 30928454. doi:10.1016/j.cgh.2019.03.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。